Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:affects |
drug metabolism
|
| gptkbp:can_increase |
plasma concentration of CYP2C19 substrates
|
| gptkbp:cause |
adverse drug reactions
|
| gptkbp:hasTherapeuticUse |
alter drug plasma levels
|
| https://www.w3.org/2000/01/rdf-schema#label |
CYP2C19 inhibitors
|
| gptkbp:include |
gptkb:isoniazid
gptkb:fluvoxamine gptkb:chloramphenicol gptkb:voriconazole gptkb:fluconazole gptkb:omeprazole gptkb:ketoconazole gptkb:lansoprazole gptkb:fluoxetine gptkb:modafinil gptkb:ticlopidine cimetidine esomeprazole |
| gptkbp:inhibitedBy |
CYP2C19 enzyme
|
| gptkbp:riskFactor |
drug-drug interactions
|
| gptkbp:bfsParent |
gptkb:Citalopram
|
| gptkbp:bfsLayer |
7
|